From what the article below says, I think it is just beginning to be made, and over in England. I don’t think it is available yet in the United States, and may take awhile to be available here with  the FDA with having to approve it before it would be avaiable. I hope I’m wrong, and that it is here in the U.S. soon, but I’m not holding my breath. Wayne

 

Fraom Previous Post:

hydrocortisone tablet that uses timed release to match circadian rhythms
Jul. 25th, 2005   10:16pm

UK company Diurnal has received orphan product designation from the European Commission for a novel treatment that uses a drug delivery technology to match the body’s circadian rhythms.

Orphan status is granted to products with a limited patient population and is designed to encourage R&D into treatments for rare diseases. It affords 10 years market exclusivity after the grant of a marketing authorisation in Europe. Other benefits include protocol assistance, access to the centralised procedure for the application for marketing authorisation and fee reductions.

The designation is for a modified release hydrocortisone tablet for the treatment of congenital adrenal hyperplasia, a genetic defect of the adrenal glands. The product is being developed by Phoqus Pharmaceuticals, a drug delivery company also based in the UK. Phoqus recently licensed a Diurnal patent that relates to delayed and sustained release therapy, and will apply its proprietary Qtrol technology to the new product.

 

The full article (press release, actually) is at http://www.in-pharmatechnologist.com/news/news-ng.asp?n=61500-drug-treatment-mimics

Betsy